Tesamorelin + Ipamorelin Blend Research: A First-Time Researcher FAQ

If you are buying for the first time, the short answer is this: tesamorelin and ipamorelin are two distinct research compounds with different signaling mechanisms, and the questions that actually determine the quality of your purchase are verification questions, not blend questions. How is purity measured and reported for each compound? Does the certificate of analysis match the lot number on the vial in your hand? Is pricing published, or hidden behind a quote form? Every compound discussed here is research-use-only material — not an FDA-approved drug, and not for human or veterinary use.

That framing matters because "blend" discussions tend to pull new buyers straight into mechanism and away from the thing that will actually cost them money: an unverifiable supply chain. This page works through the questions first-time researchers ask most, in the order a business buyer should resolve them.

The two compounds, and why they get discussed together

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a pentapeptide that research describes as a selective growth hormone secretagogue acting at the ghrelin receptor. They are frequently grouped in literature discussion because they engage different upstream points in the same broad signaling axis, and studies indicate that GHRH-analog and secretagogue classes behave differently from one another in receptor selectivity and in how their activity is characterized in vitro.

That is as far as a wholesale page should go. Research suggests meaningful differences between these classes, but the published work is research-context work, and none of it should be read as a statement about outcomes in people. For a buyer, the useful takeaway is structural: these are two separate molecules, with separate molecular weights, separate retention behavior on HPLC, and separate purity profiles. Anything that combines them has to account for all of that — which is where blend questions become sourcing questions.

Why "blend" is a procurement problem before it's a science problem

A pre-blended vial is a single container holding two different peptides. That sounds like convenience, and in handling terms it sometimes is. In verification terms, it adds work that a single-compound vial does not require.

Consider what a purity number means in a blend. On a single-compound vial, a 99%+ HPLC purity result describes one peak against everything else in the sample. In a two-compound vial, the chromatogram has two major peaks by design, and "purity" has to be defined — is it purity per component, with each compound assessed against its own impurity profile? Is it the ratio of the two compounds to one another? Is the second compound counted as an impurity of the first, or excluded from the calculation? Different suppliers answer that differently, and some never answer it at all. A blend COA that reports one undifferentiated purity figure is telling you less than it appears to.

Identity confirmation has the same issue. Mass spectrometry on a blend must resolve and confirm both species, and the report should show that it did. Stability is a third consideration: two peptides in one container share a formulation, and the conditions that suit one are not automatically ideal for the other.

None of this means blends are inherently inferior. It means a blend shifts more verification burden onto you, and a first-time buyer with no established supplier relationship is the least equipped person to carry it. Sourcing Tesamorelin 10mg and Ipamorelin 10mg as separate, individually tested catalog items gives you two clean COAs, two unambiguous purity figures, and two independently traceable lots.

The questions first-time buyers ask, and what each one really depends on

How to read a certificate of analysis like a buyer

A COA is only evidence if you can tie it to the material you received. Three checks, in order.

Lot matching. The lot or batch number printed on the COA should match the number on the vial label. A product-level COA that never changes, or one dated years before your shipment, is a marketing asset rather than a test result.

Assay coverage. Identity and purity are the headline figures, but they do not cover contamination. A multi-panel approach adds assays oriented toward what else might be present and how the material was handled. Real Peptides runs 7-panel batch testing on its catalog and publishes the results. Read the actual panel on the product page rather than taking a summary description — including this one — at face value.

Accessibility. You should be able to pull the COA yourself, without asking, without a sales call, and without paying for it. Charging for lab documentation, or releasing it only after an order is placed, inverts the logic of testing: the document exists so you can decide, not so you can be reassured after you've already committed.

If a supplier's testing is described only in prose — "third-party tested," "lab verified," "pharmaceutical grade" — with no retrievable document behind it, treat the claim as unverified. The phrase is not the evidence.

Wholesale mechanics: tiers, minimums, and landed cost

Wholesale pricing in this category is usually tiered by volume, and the mechanics are worth understanding before you compare quotes. Tiers exist because the fixed costs of a production run — synthesis setup, purification, and the testing panel itself — are spread across the lot. Larger commitments lower per-unit cost because they dilute fixed cost, not because anyone is being generous.

Minimum order quantities work the same way. A minimum is the point below which lot-level testing stops being economically rational for the supplier. Minimums differ substantially by compound and by program, and anyone quoting you a universal figure across the industry is guessing. What you should expect is that the figure is published and consistent, rather than adjusted per conversation.

When you compare suppliers, compare landed cost and risk together rather than unit price alone. Unit price ignores shipping, customs exposure on overseas fulfillment, replacement cost on failed or delayed shipments, and the cost of your own time chasing documentation. A slightly higher per-unit price from a domestic supplier who publishes COAs and ships from stock often beats a lower price that arrives weeks late with a generic document attached. Margins across this category vary widely with volume, compound, and how you position your catalog — a figure quoted to you as typical, without a source, is someone's estimate rather than a fact.

Finally, watch for pricing that only exists behind a form. Hidden pricing is not a sign of exclusivity; it usually means price is set per buyer based on what the seller thinks the buyer will pay.

The compliance questions that belong with your counsel

This section is informational and is not legal advice. The regulatory position of research-use-only materials is not a settled thing you can look up and apply — it depends on what your business does, how it is licensed, and how your jurisdiction's rules are written and interpreted.

The productive move is to arrive at your attorney's office with the right questions rather than a conclusion you found online. Reasonable starting questions include: how research-use-only labeling must be maintained through your own handling and resale; what claims your business can and cannot make in marketing; whether any state-level licensure or registration applies to your specific activity; what record-keeping obligations attach to lot traceability; and how your professional board, where you have one, views the activity you are planning.

What should be ruled out is the opposite approach — treating a supplier page, a forum post, or an industry summary as confirmation that something is permitted. Claims that a compound is unregulated, broadly permitted, or exempt are the kind of statement that only your own counsel, applying current rules to your facts, should make. Verify specifics with your attorney and your state board before you commit inventory.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around verification rather than assurance. Catalog compounds are produced to 99%+ HPLC purity and run through 7-panel batch testing. Those results are published as COAs you can check yourself before you buy — not sold separately, not released only after an order, not summarized in a sentence.

Fulfillment is domestic, with orders shipping in 5–7 days, which removes the customs and transit variability that makes overseas sourcing hard to plan inventory around. The application itself is a 3-step wholesale application rather than an open-ended qualification process.

On blends specifically, the approach favored here is the one a first-time buyer can actually audit: individually tested single-compound vials, each with its own lot and its own COA. If your research design calls for both compounds, you order both, verify both, and keep both independently traceable. Buyers building a broader catalog alongside them often work through adjacent classes such as CJC-1295 No DAC 10mg, which sits in the same general area of research interest and is documented the same way.

Where to go from here

If you are evaluating suppliers for a first order, do the verification work before the commercial conversation: pull a COA, check the lot, confirm the purity figure is reported per compound, and confirm the shipping origin. If that process satisfies you, the Wholesale Partner Program application at Real Peptides is the next step — three steps, published pricing tiers once you're approved, and documentation you can check on your own before you ever submit it.

To see how these compounds sit within the wider catalog, the Growth Factor & Tissue Signaling Research collection covers the class most relevant here, while Popular Peptides and Performance & Recovery Research show the breadth most wholesale buyers stock alongside it.

Research Use and Legal Notice

All compounds discussed on this page are sold for research use only and are not for human consumption.